ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2801

A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis

Kazuhiko Higashioka1, Masahiro Ayano1, Yasutaka Kimoto2, Hiroki Mitoma1, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horiuchi3 and Hiroaki Niro4, 1Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 4Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antibodies, CD8 cells, interleukins (IL), rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T092 ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2797–2801)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

A plethora of evidence from genome-wide association studies and relevant animal models implicates a pivotal role of T cells in the pathogenesis of rheumatoid arthritis (RA). CD8+ T cells comprise ~40% of all T cells infiltrating the rheumatoid synovium, and the number of activated CD8+ T cells in synovial fluids (SF) and peripheral blood (PB) of RA is associated with disease activity. Production of cytotoxic molecules such as granzyme B and perforin in CD8+ T cells is more pronounced in patients with RA than in healthy controls (HC).

Apart from their cytotoxicity, CD8+ T cells have recently gained attention as an IL-21-producing cell population. In mice a novel subset of IL-21-producing CD8+ T cells, like follicular helper CD4+ T cells (Tfh), is induced by IL-6 from naïve CD8+ T cells and capable of supporting B cell differentiation into Ab-producing cells. However, little is known about a role of human IL-21-producing CD8+ T cells, particularly in autoimmune diseases. Here, we have investigated a generation mechanism of IL-21-producing CD8+ T cells in humans, and also determined a role of this novel subset in patients with RA.

Methods:

CD8+ T cells in PB and SF from HC and patients with RA with or without CD3/28 stimulation were subject to the analysis of IL-21 expression at both mRNA and protein levels. To clarify a generation mechanism of IL-21-producing CD8+ T cells in humans, naïve (CD45RA+CCR7+) CD8+ T cells were highly purified using a flow cytometry and tested for their differentiation into IL-21-producing CD8+ T cells in the presence of multiple combination of cytokines along with CD3/28 stimulation. Moreover, using a flow cytometry we thoroughly analyzed the phenotype of a IL-21-producing CD8+ T cell subset in HCPB and RAPB as well as RASF. To determine whether IL-21-producing CD8+ T cells exert B-cell-helper functions, these cells were co-cultured with memory B cells.

Results:

CD3/28 stimulation induced IL-21 production in whole CD8+ T cells from HC, and central memory (CD45RA-CCR7+), but not naïve and terminal effector, CD8+ T cells were a main producer of IL-21. Among several cytokines extrapolated from studies of CD4+ T cell subsets,

IL-12 was the most potent cytokine to generate IL-21-producing CD8+ T cells from naïve CD8+ T cells. IFN-γ, IL-6 and IL-21 were also able to do so, albeit to a lesser extent. The surface phenotype of IL-21-producing CD8+ T cells was CD28+CD69+CD95+PD-1+, and these cells also had potential to produce IFN-γ, but not IL-17. Central memory CD8+ T cells stimulated with CD3/28 facilitated the differentiation from memory B cells (CD27+CD38-) to plasmablasts (CD27highCD38high) via up-regulation of expression of blimp-1 transcription factors. Compared with HCPB, central memory CD8+ T cells were pronounced in RAPB, and this trend was further prominent in RASF. Moreover, RASF enriched CD69+, CD95+ and PD-1+ CD8 + T cells than PB from HC and RA. Central memory CD8+ T cells in PB and SF from RA most significantly produced IL-21 among CD8+ T cell subsets.

Conclusion: Together, these findings suggest that IL-21-producing central memory CD8+ T cells are a novel subset that plays a pivotal role in the pathogenesis of RA by exerting B-cell-helper functions.


Disclosure: K. Higashioka, None; M. Ayano, None; Y. Kimoto, None; H. Mitoma, None; M. Akahoshi, None; Y. Arinobu, None; K. Akashi, None; T. Horiuchi, None; H. Niro, None.

To cite this abstract in AMA style:

Higashioka K, Ayano M, Kimoto Y, Mitoma H, Akahoshi M, Arinobu Y, Akashi K, Horiuchi T, Niro H. A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-novel-b-cell-helper-il-21-producing-cd8-t-cell-subset-involved-in-the-pathogenesis-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-b-cell-helper-il-21-producing-cd8-t-cell-subset-involved-in-the-pathogenesis-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology